Vassilios Papadopoulos

US Patent:

7056694, Jun 6, 2006

Filed:

Aug 11, 1999

Appl. No.:

09/762594

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Hua Li - North Potomac MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C07H 21/04
C12N 1/20
C12N 15/09
C12N 5/00
C12P 21/00

US Classification:

435 691, 435 701, 4352523, 4353201, 435325, 435 711, 536 231, 536 235, 530350

Abstract:

The present invention relates to nucleic acids encoding peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), and nucleic acids that hybridize or are variant of nucleic acids encoding the peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), which are capable of encoding proteins that regulate the function of PBRs affecting both steroid biosynthesis and mediating cholesterol delivery as well as other PBR-mediated functions.

US Patent:

7078434, Jul 18, 2006

Filed:

Aug 11, 2000

Appl. No.:

10/018448

Inventors:

Katy Drieu - Paris, FR
Vassilios Papadopoulos - North Potomac MD, US

Assignee:

Societe de Conseils de Recherches et d'Applications Scientifiques SAS - Paris
Georgetown University - Washington DC

International Classification:

A61K 31/34
A61K 36/16

US Classification:

514468, 514461, 514473, 424714

Abstract:

The present invention is directed to the use of the extract of leaves or isolated Ginkgolide B (GKB), a component of the extract of leaves in a method for decreasing the expression of peripheral-type benzodiazepine receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell. Even more particularly, the present invention is directed to the use of the extract of leaves or isolated GKB in method of decreasing cancer cell proliferation in a patient wherein the cancer cell is of the aggressive and invasive phenotype and expresses high levels of PBR in comparison to non-aggressive cancer cell.

US Patent:

7863010, Jan 4, 2011

Filed:

Sep 29, 2009

Appl. No.:

12/569511

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Thierry Hauet - Saint Benoit, FR

Assignee:

Georgetown University - Washington DC

International Classification:

G01N 33/53

US Classification:

435 72

Abstract:

The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.

US Patent:

8216798, Jul 10, 2012

Filed:

Oct 1, 2010

Appl. No.:

12/896522

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Thierry Hauet - Saint Benoit, FR

Assignee:

Georgetown University - Washington DC

International Classification:

G01N 33/53

US Classification:

435 72

Abstract:

The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.

US Patent:

7267977, Sep 11, 2007

Filed:

Mar 25, 1998

Appl. No.:

09/047652

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Martine Culty - North Potomac MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C12M 15/63

US Classification:

4353201, 4352523, 435 691, 536 231, 536 245, 514 44

Abstract:

The expression and subcellular localization of peripheral-type benzodiazepine receptors (PBR) is shown in this application to correlate with the metastatic potential of cells, and increased cell proliferation. Inhibition of PBR expression, function or stability results in a decrease in cell proliferation. Compositions and methods for regulating and/or monitoring PBR and its expression are useful for the detection, diagnosis, prognosis and treatment of solid tumors, in particular, breast cancer.

US Patent:

20030211456, Nov 13, 2003

Filed:

Mar 11, 2003

Appl. No.:

10/240052

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Katy Drieu - Paris, FR

International Classification:

C12Q001/68
A61K035/78
C12Q001/00

US Classification:

435/004000, 435/006000, 424/752000

Abstract:

The present invention is directed to a method of establishing an “identity” of leaves or isolated (GKB) or another component of the extract of leaves, by obtaining a “gene regulation profile”. The invention is also directed to a method of verifying the identity of a extract by comparing the gene regulation profile of a extract of unknown or questionable origin with the gene regulation pofile of a extract of known origin. The present invention is further directed to a method of establishing a gene expression profile of or any other component isolated from a extract, more particularly, from EGB 761.

US Patent:

20030213746, Nov 20, 2003

Filed:

Feb 13, 2003

Appl. No.:

10/181255

Inventors:

Vassilios Papadopoulos - North Potomac MD, US
Rachel Brown - Tuczon AZ, US
Caterina Cascio - Lucca Sicula, IT

International Classification:

B01D011/00

US Classification:

210/634000, 210/656000, 436/161000, 436/063000, 436/178000, 436/175000

Abstract:

One of the major problems with the diagnosis and treatment of neurological diseases is the inability of clinicians to determine the onset of disease. The present invention describes methods and kits whereby the onset of neuropathology is detected by changes in the normal levels of neurosteroids, and particularly DHEA and its metabolic precursors, in the brain and serum.

US Patent:

20040072806, Apr 15, 2004

Filed:

Mar 14, 2003

Appl. No.:

10/389189

Inventors:

Zhi-Xing Yao - Arlington VA, US
Laurent Lecanu - McLean VA, US
Gary Teper - Potomac MD, US
Janet Greeson - Las Vegas NV, US
Vassilios Papadopoulos - North Potomac MD, US

International Classification:

A61K031/56

US Classification:

514/169000, 514/177000, 514/178000

Abstract:

The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with, neurotoxicity in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The compounds of the present invention are biologically active 22R-hydroxycholesterol derivatives containing a common spirost-5-en-3-ol structure. The invention further provides a method for treating a patient having a neurological disease or disorder such as global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyper algesia, allodynia, Huntington's disease, and Parkinson's disease, by administering to the patient a therapeutically effective amount of 22R-hydroxycholesterol or a therapeutically active analog thereof.